Compare BIO-TECHNE Corp (TECH) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? BIO-TECHNE Corp trades at $72.69 (market cap $11.37B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: BIO-TECHNE Corp is far larger — about 3.3× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays the higher dividend (1.06%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 64 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| TECH | ZGN | |
|---|---|---|
Market Cap | $11.37B | $3.48B |
Volume | 2,420,565 | 1,076,161 |
Sector | Health | Consumer Cyclical |
52-Week High | $72.61 | $15.25 |
52-Week Low | $43.31 | $8.69 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | $11.39B | $4.43B |
Dividend Yield | 0.44% | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.50, near its 52-week high of $72.70, with a slight daily decline of 0.08%. Technical indicators show a bullish trend, while valuation ratios like a P/E of 62.5 suggest premium pricing. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share is a key development. Earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026, and net income declined to $73.40 million in 2025 from $168 million in 2024.
The stock's outlook is supported by the pending acquisition, offering a near-term upside to the $73.00 buyout price. However, high valuation and earnings volatility pose risks. Analyst sentiment is balanced with 46% buy ratings, but no sell recommendations. Investors should weigh the acquisition premium against fundamental concerns like margin compression.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
